Tag: Bivalirudin

1. Patients undergoing percutaneous coronary intervention (PCI) mainly via radial approach receiving either bivalirudin or heparin, in addition to P2Y12 inhibitors, following myocardial infarction experienced similar rates of death from any cause, myocardial infarction, or major bleeding. 2. Patients who had ST-segment elevation myocardial infarction (STEMI) or non-STEMI myocardial infarctions...
1. Acute coronary syndrome (ACS) patients requiring percutaneous coronary intervention (PCI) who received either heparin or bivalirudin were not significantly different in either the rates of major adverse cardiovascular events and overall adverse clinical events. 2. Use of bivalirudin in patients with ACS requiring PCI yielded a significantly lower rate...
Image: PD In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Non-publication of large randomized clinical trials: cross sectional analysis Efforts, including the listing of industry affiliations and the listing of trials on clinicaltrials.gov, have been made to improve the transparency...
Image: PD  1. Bivalirudin, initiated during transport for primary PCI in patients with STEMI, improved 30-day clinical outcomes with a reduction in major bleeding.  2. The risk of acute stent thrombosis was higher with bivalirudin, compared to unfractionated or low-molecular-weight heparin and optional glycoprotein IIb/IIIa inhibitors.  Evidence Rating Level: 1 (Excellent)  Study Rundown:...